Mymetics Corp. is a biotechnology company, which engages in the research and development of virosome based vaccines. It focuses on next generation vaccines for infectious and life disabling diseases. The company was founded in July 1994 and is headquartered in Epalinges, Switzerland.
Company profile
Ticker
MYMX
Exchange
Website
CEO
Ronald Hugo Gerard Kempers
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Ginkgo Bioworks • Bio-Techne • Denali Therapeutics ...
Former names
ICHOR CORP, PDG REMEDIATION INC
SEC CIK
Corporate docs
IRS number
251741849
MYMX stock data
Calendar
13 May 22
2 Jul 22
31 Dec 22
Financial summary
| Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
allergic, aluminum, antibody, biotech, boost, Codification, comparison, compensation, confirmed, confirming, consulting, contrast, Cooperation, cure, customary, declaration, discontinued, dose, Env, evidence, exclusive, foster, hundred, hydroxide, Immunology, inactivated, Indian, injection, leader, led, lifted, linked, modified, mouse, pending, previously, pronounced, retrospective, role, schedule, seasonal, SHIV, showed, showing, significantly, strong, superior, synergy, Targeting, today, validate, worldwide
Removed:
adding, aim, bronchial, certifying, checklist, combination, cytokine, deficiency, developing, discovered, Edgarized, ensure, exist, final, fourth, generation, group, immune, implemented, implementing, improve, inflammation, insufficient, laboratory, lung, misstatement, moved, payment, prevented, profile, program, properly, Recombinant, remedial, remediate, remediated, reverse, safety, setting, shortening, subcontracting, synthetic, therapy, TLR, undisclosed, USD, vaccinated, version
Current reports
8-K
Changes in Registrant's Certifying Accountant
17 Jun 21
8-K
Changes in Registrant's Certifying Accountant
7 Jan 20
8-K
Anergis and Mymetics Start Research Collaboration Project on the use of Virosomes for Ultra-Fast Allergy Immunotherapy
22 Apr 18
8-K/A
Financial Statements and Exhibits
25 Jan 17
8-K
Entry into a Material Definitive Agreement
30 Nov 16
8-K
Mymetics-announces discontinuation of the RSV collaborative project
28 Jan 16
8-K
Entry into a Material Definitive Agreement
23 Jun 15
8-K
Mymetics’ promising HIV vaccine candidate obtains funding to begin study at Texas Biomedical Research Institute
29 Sep 14
8-K
Mymetics Signs Agreement to Manufacture Virosome based
15 Jul 14
8-K/A
Financial Statements and Exhibits
27 Feb 14
Registration and prospectus
S-8
Registration of securities for employees
10 Apr 14
RW
Registration withdrawal request
26 Jan 05
SB-2
Registration of securities for small business issuer
6 Dec 04
424B3
Prospectus supplement
12 Aug 02
S-1/A
IPO registration (amended)
7 Aug 02
S-1
IPO registration
21 May 02
S-8
Registration of securities for employees
7 Nov 96
S-8
Registration of securities for employees
7 Nov 96
RW
Registration withdrawal request
22 Oct 96
S-3
Shelf registration
28 May 96
Proxies
DEF 14C
Information statement
7 Jan 20
PRER14C
Preliminary revised information
3 Jan 20
PRE 14C
Preliminary information
27 Dec 19
DEF 14C
Information statement
8 Nov 15
PRE 14C
Preliminary information
25 Oct 15
DEF 14C
Information statement
20 Aug 13
PRE 14C
Preliminary information
6 Aug 13
DEF 14A
Definitive proxy
28 Jun 01
PRE 14A
Preliminary proxy
18 Jun 01
Other
UPLOAD
Letter from SEC
8 Jan 20
CORRESP
Correspondence with SEC
2 Jan 20
UPLOAD
Letter from SEC
30 Dec 19
CT ORDER
Confidential treatment order
13 Feb 17
CT ORDER
Confidential treatment order
10 Sep 14
CT ORDER
Confidential treatment order
24 Mar 14
CORRESP
Correspondence with SEC
21 Feb 11
UPLOAD
Letter from SEC
21 Feb 11
UPLOAD
Letter from SEC
17 Feb 11
CORRESP
Correspondence with SEC
14 Feb 11
Patents
Utility
Oral dispersible vaccine comprising virosomes
18 Jan 22
The present disclosure is directed to oral vaccine dosage forms and processes for producing the oral vaccine dosage forms.
Utility
Oral Dispersible Vaccine Comprising Virosomes
16 Dec 21
The present disclosure is directed to oral vaccine dosage forms and processes for producing the oral vaccine dosage forms.
Utility
Methods of Improving Efficacy of Allergy Vaccines
17 Jun 20
Provided are specific immunotherapy methods for allergies in which one or more peptides specific for the allergy being treated is administered to the patient incorporated within a virosome and in the presence of a Toll-like receptor (TLR) agonist.
Utility
Oral Dispersible Vaccine Comprising Virosomes
3 Jun 20
The present disclosure is directed to oral vaccine dosage forms and processes for producing the oral vaccine dosage forms.